checkAd

Theradiag Announces Its Results for the First Half of 2021

Nachrichtenquelle: Business Wire (engl.)
20.09.2021, 07:30  |  283   |   |   

Regulatory News:

THERADIAG (Paris:ALTER) (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and Theranostics, today announces its half-year results to June 30, 2021, as approved by the Board of Directors on September 16, 2021.

H1 2021 results

In thousands of euros

H1 2021

H1 2020

% change

Revenue

5,482

4,871

+12.5 %

of which: Theranostics

2,766

2,410

+14.7 %

of which: IVD

2,716

2,461

+10.4 %

Operating income/(loss)

(178)

(423)

+57.9 %

Income/(loss) before tax and non-recurring items

(206)

(358)

+42.4 %

Net income/(loss) before non-recurring items

(23)

(146)

+84.3 %

Non-recurring items

(68)

(83)

+18.0%

Net income/(loss)

(92)

(229)

+59.8%

Bertrand de Castelnau, CEO of Theradiag, commented: “Over the last year we have been reaping the fruit of the efforts undertaken on controlling our operating costs and on our marketing strategy. Indeed, the effectiveness of our strategic refocus is demonstrated by the considerable improvement in all our financial indicators in the first half despite an economic and public health context that remains uncertain. On the basis of buoyant activity for our innovative solutions and a healthier cost structure, we are intending to accelerate Theradiag’s development by implementing a strategic plan that is in keeping with our growth ambitions on our target markets. Biotherapy monitoring is a vast global market, and the coming semesters look promising for Theradiag”.

Seite 1 von 3
Theradiag Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de



Wertpapier



0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Theradiag Announces Its Results for the First Half of 2021 Regulatory News: THERADIAG (Paris:ALTER) (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and Theranostics, today announces its half-year results to June 30, 2021, as approved by the Board of Directors on September …

Nachrichten des Autors

Titel
Titel
Titel
Titel